

中文題目：以 sofosbuvir/daclatasvir 合併治療台灣慢性 C 型肝炎患者的療效和安全性

英文題目：Efficacy and safety of sofosbuvir/daclatasvir combination therapy for Taiwanese patients with chronic hepatitis C virus infection

作者：周敬晏<sup>1</sup>, 梁博程<sup>1</sup>, 林宜竑<sup>1</sup>, 侯乃仁<sup>1</sup>, 謝明彥<sup>1</sup>, 黃駿逸<sup>1</sup>, 黃釗峰<sup>1,2,3</sup>, 葉明倫<sup>1,3</sup>, 黃志富<sup>1,3</sup>, 戴嘉言<sup>1,2,3</sup>, 莊萬龍<sup>1,3</sup>, 余明隆<sup>1,3</sup>

服務單位：<sup>1</sup>高雄醫學大學附設中和紀念醫院內科部 <sup>2</sup>健康管理中心 <sup>3</sup>高雄醫學大學醫學院醫學系

**Background:** The combination therapy with sofosbuvir and daclatasvir was reported well tolerated and achieved high sustained virological response (SVR) rates in patients with chronic hepatitis C virus (HCV) genotype 1 and/or 2 infection. Recently, APASL, EASL and AASLD guidelines-recommended sofosbuvir and daclatasvir for pan-genotype hepatitis C virus infection. The studies aimed to survey the efficacy and safety of dual therapy with sofosbuvir and daclatasvir in Taiwanese patients with HCV genotype 1 and/or 2 infection.

**Materials and Methods:**

We retrospectively analyzed clinical data from chronic HCV genotype 1 and/or 2 patients treated with sofosbuvir and daclatasvir at Kaohsiung Medical University Chung-Ho Memorial Hospital. Total 30 patients (8 males and 22 females, mean age: 65.6 ± 10.4 years) have been treated with dual therapy for 12 weeks and followed up for 12 weeks.

**Results:** All patients achieve undetectable HCV RNA at 12 weeks after cessation of therapy (SVR12). With sofosbuvir and daclatasvir therapy, 20 (66.7%) patients at week 4, 27(90%) patients at week 8 and 29 (96.7%) patients at EOT had undetectable HCV RNA (one patient with unquantifiable HCV RNA) . The serum aminotransaminase levels were improved after the treatment. The mean (range) baseline creatinine, AST, ALT and total bilirubin (T-bil) levels were: 0.85(0.53-2.31) mg/dL, 72.0(23-202) IU/L, 67.9 (15-223) IU/L and 1.15 (0.4-3.0) mg/dL. No patient experience acute exacerbation/decompensation at EOF.

**Conclusion:** We report the real-world experience of sofosbuvir and daclatasvir combination therapy which achieved very high SVR rates and was well tolerated in Taiwanese patients with HCV genotype 1 and/or 2 infection. Further results of large number of treated patients are mandatory.